Is Journey Medical Corporation (DERM) Overvalued?
We dive into why Journey Medical Corporation (DERM) could be considered overvalued on 2026-08-20, based on AAII’s Value Score and Grade.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Michael Rose
Michael Rose
Cynthia McLaughlin
Cynthia McLaughlin
Tudor Pop
| Share Statistics | DERM | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $211.7 | $618.0 | 28% |
|
| Shares Out (Mil) | 27.5 | 44.8 | 35% |
|
| Institutional Ownership | 76.3% | 85.3% | 46% |
|
| Float (Mil) | 14.9 | 47.4 | 25% |
|
| Beta | 1.08 | 0.70 | 65% |
|
| Avg Daily Volume (000s) | 303 | 390 | 50% |
|
| Price Change (52-week) |
6.1% | 68.6% | 50% |
|
| Growth | DERM | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 6.8% | 6.7% | 45% |
|
| Net Income (5yr) | (32.9%) | (1.6%) | 12% |
|
| EPS (5yr) | (24.2%) | 14.9% | 11 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (17.0%) | (14.9%) | 42% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | DERM | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $68 | $291 | 23% |
|
| Net Income (TTM) (Mil) | ($6) | ($11) | 32% |
|
| EPS (TTM) | ($0.228) | ($0.700) | 33% |
|
| Operating Cash Flow (TTM) (Mil) | ($8) | ($6) | 22% |
|
| Net Cash Flow (TTM) (Mil) | na | $5 | na |
|
| Long-Term Debt (Q1) (Mil) | $21 | $6 | 33% |
|
| Enterprise Value (Q1) (Mil) | $188 | $450 | 26% |
|
| Valuation | DERM | Industry Median |
Percentile (All Stocks) |
|
| P/B | 6.47 | 2.78 | 83% |
|
| P/E | na | 17.4 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | DERM | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 65.5% | 67.0% | 77% |
|
| Net Margin | (9.0%) | (2.3%) | 22% |
|
| ROA | (6.8%) | (22.4%) | 28% |
|
| ROE | (23.8%) | (20.2%) | 22% |
|
| Liabilities to Assets | 67.3% | 32.2% | 63% |
|
| F-Score | 3 | 3 | 18% |
|
Journey Medical Corporation did not pass any screens on 8/20/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors